<!-- source: https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/LOKELMA-myAZ-integration_Phase4?node-id=677-7514 -->

+------------------------------------+
| **Hero-Banner**                    |
+------------------------------------+
| ![Banner Background](images/hyperkalemia/41b14afc6408fc20d6abf3107dd5af6ecdfc7bd4.png) |
+------------------------------------+
| # About Hyperkalemia               |
+------------------------------------+

---

## Hyperkalemia is an electrolyte disorder<sup>1</sup>

---

### Predisposing factors:<sup>1-5</sup>

+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+
| **Columns-Factors**                                                                                                                                                                                                                                                                                                                                                   |
+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+
| ![Heart Failure Icon](images/hyperkalemia/933c398694871c3b53aa5d288df8340ab35da643.png)           | ![Type 2 Diabetes Icon](images/hyperkalemia/dd337acbe12d50de291c9c3767f3b4349bb53c89.png)         | ![Chronic Kidney Disease Icon](images/hyperkalemia/51dbe19dbb9f912d8682a8bdd8f83bc00546717d.png) | ![RAASi Icon](images/hyperkalemia/dd337acbe12d50de291c9c3767f3b4349bb53c89.png)                  |
|                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      |
| **HF**                                                                                               | **T2D**                                                                                              | **CKD**                                                                                              | **Concomitant RAASi use**                                                                            |
+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+

---

In studies, the incidence of hyperkalemia over follow-up duration of approximately 1 year was observed to be:<sup>6</sup>

---

+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+
| **Columns-Statistics**                                                                                                                                                                                                                                                                                     |
+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+
| ![Pie chart showing less than 5 percent](images/hyperkalemia/7617fc50df3a42e2e2e9e62c9eff90c7b9c91fb9.svg) | ![Pie chart showing 40 percent](images/hyperkalemia/d10de9d95a6f4194623aee1bc4f0e180d7705b31.svg)        | ![Pie chart showing approximately 73 percent](images/hyperkalemia/65f7720faae2f19639fd728c201ae8a9ed58ffde.svg) |
|                                                                                                      |                                                                                                      |                                                                                                      |
| **<5%**                                                                                              | **Up to 40%**                                                                                        | **~73%**                                                                                             |
|                                                                                                      |                                                                                                      |                                                                                                      |
| with HF                                                                                              | with chronic HF                                                                                      | with CKD                                                                                             |
+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------+

---

+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Columns-Callout**                                                                                                                                                                                                               |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Diabetes Canada guidelines recommend sodium zirconium cyclosilicate as a treatment option in patients with moderate to high potassium<sup>1</sup>                                                                                 |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

---

+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Columns-Callout**                                                                                                                                                                                                               |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| KDIGO guidelines recommend potassium binders as a treatment option for RAASi-induced hyperkalemia<sup>7*</sup>                                                                                                                    |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

---

## Footnotes

\* Practice points are consensus-based statements representing the expert judgment of the Work Group and are not graded. Although these statements are developed based on a different methodology, they should not be seen as "less important" or a "downgrade" from graded recommendations.<sup>7</sup>

CKD=chronic kidney disease; HF=heart failure; RAASi=Renin-angiotensin-aldosterone system inhibitor; T2D=Type 2 diabetes.

---

## References

1. Tobe SW, et al. Chronic kidney disease in diabetes: A clinical practice guideline. *Can J Diabetes.* 2025;49:73-86.
2. Kovesdy CP. Updates in hyperkalemia: Outcomes and therapeutic strategies. *Rev Endocr Metab Disord.* 2017;18(1):41-47.
3. Michel A, et al. Risk factors for hyperkalemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. *European Journal of Heart Failure.* 2015;17:205-213.
4. Weir MR, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. *N Engl J Med.* 2015;372:211-221.
5. National Kidney Foundation. Clinical update on hyperkalemia. A chronic risk for CKD patients and a potential barrier to recommended CKD treatment. 2014. https://www.kidney.org/sites/default/files/02-10-6785_HBE_Hyperkalemia_Bulletin.pdf Accessed April 11, 2025.
6. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2021 Sep 21;42(36):3599-3726.
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int.* 2024;105(4S):S117-S314.
